PT3378859T - Derivado de benzofurano, método de preparação do mesmo e uso do mesmo em medicina - Google Patents

Derivado de benzofurano, método de preparação do mesmo e uso do mesmo em medicina

Info

Publication number
PT3378859T
PT3378859T PT168656718T PT16865671T PT3378859T PT 3378859 T PT3378859 T PT 3378859T PT 168656718 T PT168656718 T PT 168656718T PT 16865671 T PT16865671 T PT 16865671T PT 3378859 T PT3378859 T PT 3378859T
Authority
PT
Portugal
Prior art keywords
same
medicine
preparation
benzofuran derivative
benzofuran
Prior art date
Application number
PT168656718T
Other languages
English (en)
Inventor
Lu Biao
Shen Xiaodong
He Mingxun
Liu Dong
Zhang Minsheng
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of PT3378859T publication Critical patent/PT3378859T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
PT168656718T 2015-11-19 2016-11-02 Derivado de benzofurano, método de preparação do mesmo e uso do mesmo em medicina PT3378859T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510800975 2015-11-19

Publications (1)

Publication Number Publication Date
PT3378859T true PT3378859T (pt) 2019-12-11

Family

ID=58717310

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168656718T PT3378859T (pt) 2015-11-19 2016-11-02 Derivado de benzofurano, método de preparação do mesmo e uso do mesmo em medicina

Country Status (20)

Country Link
US (2) US10759787B2 (pt)
EP (1) EP3378859B1 (pt)
JP (1) JP6828229B2 (pt)
KR (2) KR20180081587A (pt)
CN (1) CN107428742B (pt)
AU (1) AU2016357900B2 (pt)
BR (1) BR112018007876B1 (pt)
DK (1) DK3378859T3 (pt)
ES (1) ES2760510T3 (pt)
HR (1) HRP20192209T1 (pt)
HU (1) HUE047785T2 (pt)
LT (1) LT3378859T (pt)
MX (1) MX380122B (pt)
PL (1) PL3378859T3 (pt)
PT (1) PT3378859T (pt)
RS (1) RS59763B1 (pt)
RU (1) RU2727198C2 (pt)
SI (1) SI3378859T1 (pt)
TW (1) TWI718207B (pt)
WO (1) WO2017084494A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
EP3626715A4 (en) * 2017-05-18 2021-03-24 Jiangsu Hengrui Medicine Co., Ltd. CRYSTAL OF A BENZOFURAND DERIVATIVE-FREE BASE AND MANUFACTURING PROCESS
KR102635949B1 (ko) 2017-05-18 2024-02-14 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 종양 치료용 약물의 제조에 있어서의 ezh2 억제제 및 btk 억제제의 조합물의 용도
TWI717656B (zh) * 2017-11-10 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 苯並呋喃衍生物的製備方法
MX2020007974A (es) 2018-01-31 2020-09-07 Mirati Therapeutics Inc Inhibidores de complejo represivo polycomb 2 (prc2).
CN110179796B (zh) * 2018-02-23 2023-01-24 江苏恒瑞医药股份有限公司 一种苯并呋喃类衍生物的组合物及制备方法
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN112512580B (zh) * 2018-09-29 2024-04-16 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
WO2020192652A1 (zh) 2019-03-25 2020-10-01 上海华汇拓医药科技有限公司 酰胺类化合物制备方法及其在医药领域的应用
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN113302185B (zh) * 2019-04-29 2024-04-09 上海和誉生物医药科技有限公司 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用
WO2020228591A1 (zh) * 2019-05-10 2020-11-19 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的制备方法
CN110003187B (zh) * 2019-05-10 2021-11-05 南京工业大学 一种多氟烷基取代苯并呋喃类化合物及其制备方法
CN112007162B (zh) * 2019-05-30 2023-05-12 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
WO2020259667A1 (zh) * 2019-06-28 2020-12-30 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
TW202114670A (zh) * 2019-09-30 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 一種ezh2抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤藥物中的用途
WO2021063340A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途
WO2021063331A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途
CN112870365A (zh) * 2019-11-29 2021-06-01 江苏恒瑞医药股份有限公司 Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途
AU2022340500A1 (en) 2021-08-30 2024-04-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma
CA3234851A1 (en) 2021-10-15 2023-04-20 Ya CHEN Method for preparing benzofuran derivative
EP4536649A1 (en) 2022-06-13 2025-04-16 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
KR20250023481A (ko) 2022-06-13 2025-02-18 트리라인 바이오사이언시스, 인크. 1,8-나프티리딘-2-온 이종이작용성 bcl6 분해제
TW202602861A (zh) * 2024-03-08 2026-01-16 新加坡商歐托梅拉公司 用於靶向自噬之苯并呋喃衍生物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
ATE539070T1 (de) * 2008-02-14 2012-01-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インダゾール
EA023788B1 (ru) * 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
EP2410171A1 (en) 2010-07-23 2012-01-25 Ewt Ip B.V. Wind turbine having a rotor with hub
SG180031A1 (en) 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
EP2755962B1 (en) * 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
CA2850570A1 (en) * 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
WO2014177982A1 (en) 2013-04-30 2014-11-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US9822103B2 (en) * 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
LT3121175T (lt) 2014-03-17 2020-03-10 Daiichi Sankyo Company, Limited 1,3-benzodioksazolo dariniai, kaip ezh1 ir (arba) ezh2 inhibitoriai

Also Published As

Publication number Publication date
AU2016357900B2 (en) 2020-09-17
CA3002436A1 (en) 2017-05-26
BR112018007876B1 (pt) 2023-10-17
RU2018119173A3 (pt) 2020-02-13
EP3378859A1 (en) 2018-09-26
RU2727198C2 (ru) 2020-07-21
LT3378859T (lt) 2020-01-27
MX380122B (es) 2025-03-11
PL3378859T3 (pl) 2020-04-30
TW201718561A (zh) 2017-06-01
HK1243414A1 (zh) 2018-07-13
MX2018005019A (es) 2018-06-13
ES2760510T3 (es) 2020-05-14
SI3378859T1 (sl) 2020-03-31
JP6828229B2 (ja) 2021-02-10
HRP20192209T1 (hr) 2020-07-24
RU2018119173A (ru) 2019-12-19
BR112018007876A2 (pt) 2018-10-30
US11059811B2 (en) 2021-07-13
RS59763B1 (sr) 2020-02-28
US10759787B2 (en) 2020-09-01
KR20250028514A (ko) 2025-02-28
HUE047785T2 (hu) 2020-05-28
TWI718207B (zh) 2021-02-11
CN107428742B (zh) 2020-05-08
EP3378859A4 (en) 2018-09-26
EP3378859B1 (en) 2019-10-30
US20180327394A1 (en) 2018-11-15
DK3378859T3 (da) 2020-01-20
AU2016357900A1 (en) 2018-05-24
CN107428742A (zh) 2017-12-01
WO2017084494A1 (zh) 2017-05-26
KR20180081587A (ko) 2018-07-16
US20200354349A1 (en) 2020-11-12
JP2018538257A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
PT3378859T (pt) Derivado de benzofurano, método de preparação do mesmo e uso do mesmo em medicina
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
IL259571A (en) Cannabis oil compositions and methods for preparation thereof
IL256652A (en) Therapeutic compositions, combinations, and methods of use
IL264454A (en) Novel compositions, uses and methods for making them
BR112017019276A2 (pt) artigo compósito, método de fabricação de artigo compósito, uso de artigo compósito, dispositivo, método de fabricação de um dispositivo, compósito e método
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
PT3546457T (pt) Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo
IL254734B1 (en) Modified t cells and methods of making and using the same
HUE057289T2 (hu) Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása
BR112016030968A2 (pt) análogos de pridopidina, preparação e uso destes
HUE049341T2 (hu) Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására
IL249061A0 (en) Combination, composition, and method of administering the combination or composition to animals
HRP20260361T1 (hr) Supstituirani 4-fenilpiperidini, njihova priprava i uporaba
IL246837B (en) Antibodies, pharmaceutical compositions and uses thereof
IL256381A (en) Cryoprecipitate compositions and methods of preparation thereof
IL280148B (en) Methods and apparatus for simulating interaction of radiation with structures, metrology methods and apparatus, device manufacturing method
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
IL257340A (en) Converted benzaimidazoles, methods for their preparation and use as pharmaceuticals
IL256833A (en) Il-17f-specific capture agents, compositions, and methods of using and making
PT3265123T (pt) Anticorpos, usos e métodos
DK3315181T3 (da) Sammensat emne og fremgangsmåde til at fremstille samme
IL262929A (en) Composition, and application and pharmaceutical preparation thereof
IL263969A (en) Benzodioxane derivatives and their pharmaceutical use
IL258381A (en) Oil compositions and methods of making